Cardiovascular
Does Cholesterol Ratio Matter If Everything Else Is Normal? A Look at the Clinical Trials
Your doctor says your cholesterol numbers look fine — but your ratio tells a different story. Research shows that cardiovascular risk can be hiding in plain sight even when total cholesterol, blood pressure, and blood sugar appear normal. Understanding which ratios actually predict events — and which companion markers like CRP and homocysteine fill in the gaps — could change how you approach your heart health entirely.
Does Cholesterol Ratio Matter If Everything Else Is Normal?
Most people leave a routine physical feeling reassured when the doctor says, "Your cholesterol looks fine." But cardiologists and lipid researchers have been quietly shifting their focus away from single-number readings toward something more predictive: cholesterol ratios. The question isn't just whether your LDL is under 130 mg/dL — it's whether your lipid particles are in the right relationship to one another, and whether other silent markers like high-sensitivity CRP and homocysteine are amplifying risk you can't see on a basic panel.
So does cholesterol ratio matter if everything else is normal? Based on the clinical evidence, the answer is a qualified but important yes — and here's why that distinction should change how you read your next lab report.
---
What Cholesterol Ratios Are Actually Measuring
A standard lipid panel reports total cholesterol (TC), LDL, HDL, and triglycerides as separate numbers. Ratios combine these figures into a single index that captures how well your body is managing reverse cholesterol transport — the process by which HDL pulls cholesterol away from artery walls and delivers it to the liver for disposal.
The two most clinically studied ratios are:
| Ratio | Formula | Optimal Target | High Risk Threshold |
|---|---|---|---|
| TC/HDL (Castelli ratio) | Total cholesterol ÷ HDL | < 3.5 | > 5.0 |
| LDL/HDL | LDL ÷ HDL | < 2.0 | > 3.5 |
| Triglyceride/HDL | Triglycerides ÷ HDL | < 2.0 | > 3.0 |
| Non-HDL cholesterol | TC − HDL | < 130 mg/dL | > 160 mg/dL |
The triglyceride/HDL ratio deserves special attention because it serves as a proxy for insulin resistance and small dense LDL particle concentration — two factors that dramatically accelerate plaque formation but are invisible on a basic panel (Millán et al., Cardiovascular Diabetology 2009; PMID: 19320986).
A landmark analysis from the Physicians' Health Study found that the TC/HDL ratio outperformed LDL alone as a predictor of myocardial infarction in apparently healthy men over an 8-year follow-up (Stampfer et al., New England Journal of Medicine 1991; PMID: 1995384). Subjects with "normal" LDL but unfavorable ratios had substantially elevated event rates — exactly the population that would slip through a standard cholesterol screen.
---
Does Total Cholesterol Matter If Everything Else Is Normal?
This is where population-level data gets genuinely complicated. Total cholesterol is a blunt instrument. HDL cholesterol — the "good" fraction — is included in the total, meaning someone with TC of 220 mg/dL and HDL of 75 mg/dL has a TC/HDL ratio of 2.93, which is actually cardioprotective.
Conversely, a person with TC of 185 mg/dL and HDL of only 38 mg/dL carries a ratio of 4.87, placing them in moderate-to-high risk territory despite a number many clinicians would dismiss without discussion.
Meta-analyses from the Emerging Risk Factors Collaboration — which pooled data from 302,430 individuals across 68 prospective studies — found that when HDL and non-HDL cholesterol were accounted for, total cholesterol in isolation added limited independent predictive value beyond ratio-based measures (Di Angelantonio et al., JAMA 2009; PMID: 19903920).
The practical takeaway: total cholesterol matters far less than the context in which it appears. If your TC is 210 but your HDL is 72 and your triglycerides are 85, your ratio profile is excellent. If your TC is 190 but your HDL is 41 and your triglycerides are 195, you have a developing risk picture that a headline number hides entirely.
---
Does CRP Matter If Everything Else Is Normal?
High-sensitivity C-reactive protein (hs-CRP) is one of the most important cardiovascular biomarkers that primary care panels routinely omit. CRP is an acute-phase reactant produced by the liver in response to systemic inflammation — and chronic low-grade inflammation is now understood to be a primary driver of atherosclerotic plaque rupture, not merely plaque formation.
The JUPITER trial, one of the largest statin trials ever conducted, specifically enrolled people with normal LDL (< 130 mg/dL) but elevated hs-CRP (≥ 2.0 mg/L). In 17,802 participants followed for a median of 1.9 years, rosuvastatin reduced cardiovascular events by 44% and all-cause mortality by 20% — in a population most clinicians would have considered low risk based on standard lipid panels alone (Ridker et al., New England Journal of Medicine 2008; PMID: 18997196).
The American Heart Association currently classifies hs-CRP risk as:
- Low risk: < 1.0 mg/L
- Average risk: 1.0–3.0 mg/L
- High risk: > 3.0 mg/L
So does CRP matter if everything else is normal? Absolutely. An hs-CRP above 2.0 mg/L in the context of a favorable lipid panel still meaningfully elevates cardiovascular risk — and it signals that dietary patterns, visceral fat, gut health, or chronic infection are driving inflammation that cholesterol numbers alone won't capture.
For interventions, omega-3 fatty acids (EPA and DHA) have demonstrated consistent hs-CRP reduction in randomized controlled trials. A meta-analysis of 68 trials found significant reductions in CRP, IL-6, and TNF-α with omega-3 supplementation, particularly at doses of 2g+ EPA/DHA daily (Calder, British Journal of Nutrition 2012; PMID: 22571889).
---
Does Homocysteine Matter If Everything Else Is Normal?
Homocysteine is an amino acid byproduct of methionine metabolism. Elevated plasma homocysteine (hyperhomocysteinemia, typically defined as > 15 µmol/L) is associated with endothelial dysfunction, oxidative stress, and direct vascular injury — mechanisms that operate independently of lipid levels.
A meta-analysis published in the Journal of the American Medical Association found that each 5 µmol/L increase in homocysteine was associated with a 20% increase in coronary artery disease risk after adjustment for traditional cardiovascular risk factors (Wald et al., BMJ 2002; PMID: 11839633). Importantly, this association persisted even in individuals with otherwise unremarkable lipid panels.
Elevated homocysteine is most commonly driven by deficiencies in:
- Folate (B9)
- Vitamin B12
- Vitamin B6
- Riboflavin (B2) in individuals with the MTHFR polymorphism
Does homocysteine matter if everything else is normal? The evidence says yes — particularly for individuals over 40, those with MTHFR variants (estimated at 40–60% of the population), vegans and vegetarians at risk for B12 deficiency, and anyone with a family history of early cardiovascular events.
Reducing homocysteine through B-vitamin supplementation lowers plasma levels reliably, though whether this translates to reduced cardiovascular events remains debated. The VITATOPS trial (8,164 patients) showed a 24% reduction in stroke, MI, and vascular death over 5 years with B-vitamin therapy in high-risk patients (VITATOPS Trial Study Group, Lancet Neurology 2010; PMID: 20594812). Even if the effect size is modest, the cost and risk profile of B-vitamin therapy makes it a reasonable consideration when homocysteine is elevated.
---
Does A1C Matter If Everything Else Is Normal?
Hemoglobin A1C (glycated hemoglobin) reflects average blood glucose over the prior 2–3 months. While it's primarily used to diagnose and monitor diabetes, emerging evidence positions A1C as an independent cardiovascular risk factor — even within ranges considered "normal" or "prediabetic."
The Atherosclerosis Risk in Communities (ARIC) study demonstrated that A1C levels in the range of 5.5–6.4% (considered "prediabetic" by ADA standards) were associated with significantly higher incidence of coronary heart disease and ischemic stroke compared to those with A1C below 5.0%, independent of fasting glucose and traditional lipid values (Selvin et al., Annals of Internal Medicine 2010; PMID: 20083828).
This matters in the context of cholesterol ratios because elevated blood glucose directly modifies LDL particles through glycation, producing small-dense glycated LDL that is more atherogenic and less efficiently cleared by LDL receptors. In other words, an A1C creeping toward 5.7% can worsen the cardiovascular impact of a ratio that appears borderline — acting as a silent multiplier on a lipid profile that looks acceptable in isolation.
For this reason, integrative cardiology approaches increasingly evaluate TC/HDL ratio, triglyceride/HDL ratio, hs-CRP, homocysteine, and A1C as a cluster, not in isolation.
---
What This Means for Your Formula
Understanding which biomarkers to track is only half the challenge — the other half is knowing which evidence-based interventions move the needle on each one. This is where personalized supplementation, built on actual lab data, earns its place alongside dietary changes and exercise.
For CRP and inflammatory cardiovascular risk, Ones includes pharmaceutical-grade Omega-3 (EPA/DHA) at doses calibrated to clinical ranges — the 2g+ threshold where hs-CRP reductions become statistically meaningful in RCTs. Unlike fixed multivitamins, Ones formulas adjust this dose based on your triglyceride/HDL ratio and hs-CRP from your blood work, not population averages.
For homocysteine, Ones incorporates active B-complex support including methylated folate and B12 (methylcobalamin) — the bioavailable forms that work even in individuals with MTHFR variants who cannot efficiently convert synthetic folic acid. This is a specificity that over-the-counter B-complex supplements often miss.
For endothelial function and oxidative stress — the downstream effects of elevated homocysteine and glycated LDL — CoQ10/Ubiquinol at 200mg provides mitochondrial and vascular protection supported by multiple trials in cardiovascular populations. Ubiquinol is the reduced, more bioavailable form, and Ones uses this version specifically for individuals whose panels suggest elevated oxidative stress burden.
If your ratios, CRP, or homocysteine values are elevated, understanding your cardiovascular biomarkers in depth is a productive first step before choosing any supplement protocol. You can also explore how omega-3 dosing affects lipid ratios and inflammation in clinical detail.
---
Key Takeaways
- Cholesterol ratios (TC/HDL, LDL/HDL, TG/HDL) are more predictive of cardiovascular events than total cholesterol or LDL alone, particularly in people who appear low-risk on standard panels.
- Total cholesterol as a standalone number is insufficient — its meaning depends entirely on the HDL fraction and broader lipid context.
- hs-CRP above 2.0 mg/L significantly elevates cardiovascular risk even with normal lipid numbers, as demonstrated in the JUPITER trial with 17,802 participants.
- Homocysteine above 15 µmol/L independently increases coronary artery disease risk by approximately 20% per 5 µmol/L increment, and responds well to methylated B-vitamin therapy.
- A1C in the prediabetic range (5.5–6.4%) amplifies atherogenic risk by glycating LDL particles and worsening the impact of borderline lipid ratios.
- A cluster-based approach — evaluating ratios, CRP, homocysteine, and A1C together — provides a far more accurate cardiovascular risk picture than any single value in isolation. Always consult a healthcare provider before making clinical decisions based on lab results.